A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors.
Gerald S. Falchook(The University of Texas MD Anderson Cancer Center), Anthony J. Olszanski(Fox Chase Cancer Center), Michael H. Shaw(Takeda (United States)), James Strauss(Texas Oncology), Pei Jye Voon(University Health Network), Kristin H. Horn(Takeda (United States)), Kate Stumpo(Takeda (United States)), Richard C. Gregory(Institute for Learning and Development), Jason J. Luke(University of Chicago), Patricia LoRusso(Yale Cancer Center), Karim Malek(ImmunoGen (United States)), Cong Li(Takeda (United States)), Neil Lineberry(Institute for Learning and Development), Xīn Gào(Qingdao University), John P. Gibbs(Takeda (United States))
Cited by 10
Related Papers
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns
|Nature Genetics|2000|1.4k
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
|The Lancet Oncology|2012|1.3k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835